Perspective Therapeutics, Inc. (CATX)

Price$3.03

Value ScoreD

Growth ScoreF

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)21.01%

Price vs S&P 500 (4W)-19.41%

VGM Score24.79

Market Capitalization$345.56M

All Metrics

Book Value / Share (Quarterly)$3.05

P/TBV (Annual)1.22x

Revenue Growth (3Y)-37.09%

Cash Flow / Share (Quarterly)$-0.94

Price vs S&P 500 (YTD)2.02%

Gross Margin (TTM)22.97%

Net Profit Margin (TTM)-17982.69%

EPS (TTM)$-1.40

10-Day Avg Trading Volume1.54M

EPS Excl Extra (TTM)$-1.40

Revenue Growth (5Y)-38.50%

EPS (Annual)$-1.40

ROI (Annual)-49.42%

Gross Margin (Annual)23.10%

Net Profit Margin (5Y Avg)-4127.01%

Cash / Share (Quarterly)$2.38

Revenue Growth QoQ (YoY)-77.78%

ROA (Last FY)-38.63%

Revenue Growth TTM (YoY)-57.99%

EBITD / Share (TTM)$-1.43

ROE (5Y Avg)-32.85%

Operating Margin (TTM)-19419.58%

Cash Flow / Share (Annual)$-1.28

P/B Ratio0.99x

P/B Ratio (Quarterly)1.37x

Net Income / Employee (Annual)$-632,600

EV / Revenue (TTM)474.43x

Net Interest Coverage (TTM)-3.35x

ROA (TTM)-34.64%

EPS Incl Extra (Annual)$-1.40

Current Ratio (Annual)5.17x

Quick Ratio (Quarterly)8.61x

3-Month Avg Trading Volume2.82M

52-Week Price Return-2.88%

Revenue / Employee (TTM)$3,800

Tangible BV / Share (Quarterly)$2.70

P/S Ratio (Annual)390.90x

Asset Turnover (Annual)0.00x

52-Week High$6.16

Operating Margin (5Y Avg)-4448.67%

EPS Excl Extra (Annual)$-1.40

CapEx CAGR (5Y)99.28%

26-Week Price Return28.94%

Quick Ratio (Annual)5.08x

13-Week Price Return-40.59%

Total Debt / Equity (Annual)0.01x

Current Ratio (Quarterly)8.75x

Enterprise Value$293.20M

Revenue / Share Growth (5Y)-34.13%

Asset Turnover (TTM)0.00x

Revenue / Employee (Annual)$5,400

Inventory Turnover (Annual)5.19x

Pretax Margin (Annual)-11813.12%

Cash / Share (Annual)$1.95

3-Month Return Std Dev63.53%

Gross Margin (5Y Avg)42.29%

Net Income / Employee (TTM)$-681,800

ROE (Last FY)-49.81%

Net Interest Coverage (Annual)-2.38x

EPS Basic Excl Extra (Annual)$-1.40

Receivables Turnover (TTM)9.09x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.40

Receivables Turnover (Annual)14.49x

ROI (TTM)-41.59%

P/S Ratio (TTM)559.16x

Pretax Margin (5Y Avg)-4083.08%

Revenue / Share (Annual)$0.01

Tangible BV / Share (Annual)$2.25

Price vs S&P 500 (52W)-27.25%

Year-to-Date Return10.18%

5-Day Price Return-17.21%

EPS Normalized (Annual)$-1.40

ROA (5Y Avg)-26.66%

Net Profit Margin (Annual)-11665.27%

Month-to-Date Return-23.10%

Cash Flow / Share (TTM)$-0.06

EBITD / Share (Annual)$-1.49

Operating Margin (Annual)-12846.61%

LT Debt / Equity (Annual)0.01x

ROI (5Y Avg)-32.46%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.40

P/TBV (Quarterly)1.55x

P/B Ratio (Annual)0.99x

Inventory Turnover (TTM)4.82x

Pretax Margin (TTM)-18194.17%

Book Value / Share (Annual)$2.79

Price vs S&P 500 (13W)-48.84%

Beta1.77x

Revenue / Share (TTM)$0.01

ROE (TTM)-41.84%

52-Week Low$1.96

vGradeD

gGradeF

mGradeD

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.25est. -0.30

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.10

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
CATXPerspective Therapeutics, Inc.	D	F	D	$3.03
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Perspective Therapeutics develops targeted radiopharmaceuticals using Lead-212, an alpha-emitting isotope designed to deliver radiation directly to cancer cells. The company's approach aims to improve treatment efficacy while reducing harm to healthy tissue. This technology addresses a significant market need for more selective cancer therapies across multiple tumor types.